Skip to main content
SpringerLink
Log in

Mesothelial Tumors of the Pleura

  • Chapter
  • First Online:
Diagnostic Thoracic Pathology

  • 1360 Accesses

Abstract

Primary tumors of the pleura are relatively rare lesions, being far outnumbered by metastatic disease to the pleural surfaces. Tumors of mesothelial origin represent a subgroup of these tumors and malignant mesothelioma is the most common primary malignant neoplasm of the pleural surfaces. Malignant mesothelioma is a highly aggressive malignancy that responds poorly to treatment and has a dismal overall survival (Zellos and Sugarbaker, Semin Oncol 29:41–50, 2002; Edwards et al., Thorax 55:731–5, 2000; Scherpereel et al., Eur Respir J 35:479–95, 2010). Malignant mesothelioma is a heterogeneous disease with different histological patterns and genomic characteristics. The vast majority of cases are attributable to asbestos exposure and typically develop after a long latency period (Wagner et al., Br J Ind Med 17:260–71, 1960; Astoul et al., Respiration 83:481–93, 2012). This long latency is to blame for the rising incidence of mesothelioma cases, despite the ban of mining, processing, and use of asbestos in many industrialized countries. Studies with the aim of identifying targetable mutations in mesothelioma are currently ongoing as novel therapeutic strategies are being sought. Benign mesothelial tumors, on the other hand, are extremely rare in the pleural cavity despite their more frequent occurrence in other mesothelial-lined spaces, such as the peritoneum or the genitourinary tract.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Zellos LS, Sugarbaker DJ. Multimodality treatment of diffuse malignant pleural mesothelioma. Semin Oncol. 2002;29:41–50.

    Article  PubMed  Google Scholar 

  2. Edwards JG, Abrams KR, Leverment JN, et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 2000;55:731–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Scherpereel A, Astoul P, Baas P, European Respiratory Society/European Society of Thoracic Surgeons Task Force, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35:479–95.

    Article  CAS  PubMed  Google Scholar 

  4. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Astoul P, Roca E, Galateau-Salle F, et al. Malignant pleural mesothelioma: from the bench to the bedside. Respiration. 2012;83:481–93.

    Article  CAS  PubMed  Google Scholar 

  6. Golden A, Ash JE. Adenomatoid tumors of the genital tract. Am J Pathol. 1945;21:63–79.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Mackay B, Bennington JL, Skoglund RW. The adenomatoid tumor: fine structural evidence for a mesothelial origin. Cancer. 1971;27:109–15.

    Article  CAS  PubMed  Google Scholar 

  8. Isotalo PA, Keeney GL, Sebo TJ, et al. Adenomatoid tumor of the adrenal gland: a clinicopathologic study of five cases and review of the literature. Am J Surg Pathol. 2003;27:969–77.

    Article  PubMed  Google Scholar 

  9. Natarajan S, Luthringer DJ, Fishbein MC. Adenomatoid tumor of the heart: report of a case. Am J Surg Pathol. 1997;21:1378–80.

    Article  CAS  PubMed  Google Scholar 

  10. Yeh CJ, Chuang WY, Chou HH, et al. Multiple extragenital adenomatoid tumors in the mesocolon and omentum. APMIS. 2008;116:1016–9.

    Article  PubMed  Google Scholar 

  11. Kaplan MA, Tazelaar HD, Hayashi T, et al. Adenomatoid tumors of the pleura. Am J Surg Pathol. 1996;20:1219–23.

    Article  CAS  PubMed  Google Scholar 

  12. Ikuta N, Tano M, Iwata M, et al. A case of adenomatoid mesothelioma of the pleura. Nihon Kyobu Shikkan Gakkai Zasshi. 1989;27:1540–4.

    CAS  PubMed  Google Scholar 

  13. Minato H, Nojima T, Kurose N, et al. Adenomatoid tumor of the pleura. Pathol Int. 2009;59:567–71.

    Article  PubMed  Google Scholar 

  14. Handra-Luca A, Couvelard A, Abd Alsamad I, et al. Adenomatoid tumor of the pleura. Case Rep Ann Pathol. 2000;20:369–72.

    CAS  Google Scholar 

  15. Erber R, Warth A, Muley T, et al. BAP1 loss is a useful adjunct to distinguish malignant mesothelioma including the adenomatoid-like variant from benign adenomatoid tumors. Appl Immunohistochem Mol Morphol. 2020;28:67–73.

    Article  CAS  PubMed  Google Scholar 

  16. Takeda M, Kasai T, Enomoto Y, et al. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int. 2010;60:395–9.

    Article  PubMed  Google Scholar 

  17. Goode B, Joseph NM, Stevers M, et al. Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation. Mod Pathol. 2018;31:660–73.

    Article  CAS  PubMed  Google Scholar 

  18. Weissferdt A, Kalhor N, Suster S. Malignant mesothelioma with prominent adenomatoid features: a clinicopathologic and immunohistochemical study of 10 cases. Ann Diagn Pathol. 2011;15:25–9.

    Article  PubMed  Google Scholar 

  19. Miles JM, Hart WR, McMahon JT. Cystic mesothelioma of the peritoneum. Report of a case with multiple recurrences and review of the literature. Cleve Clin Q. 1986;53:109–14.

    Article  CAS  PubMed  Google Scholar 

  20. Pelosi G, Zannoni M, Caprioli F, et al. Benign multicystic mesothelial proliferation of the peritoneum: immunohistochemical and electron microscopical study of a case and review of the literature. Histol Histopathol. 1991;6:575–83.

    CAS  PubMed  Google Scholar 

  21. Weiss SW, Tavassoli FA. Multicystic mesothelioma. An analysis of pathologic findings and biologic behavior in 37 cases. Am J Surg Pathol. 1988;12:737–46.

    Article  CAS  PubMed  Google Scholar 

  22. Ball NJ, Urbanski SJ, Green FH, et al. Pleural multicystic mesothelial proliferation. The so-called multicystic mesothelioma. Am J Surg Pathol. 1990;14:375–8.

    Article  CAS  PubMed  Google Scholar 

  23. Katoh S, Satoh M, Oouchi H, et al. Pleural multicystic mesothelial proliferation. Chest. 1994;105:295–6.

    Article  CAS  PubMed  Google Scholar 

  24. Şentürk E, Çokpınar S, Şen S, et al. Pleural multicystic mesothelial proliferation that presented with hemothorax. Tuberk Toraks. 2013;61:47–9.

    Article  PubMed  Google Scholar 

  25. Agarwal S, Mullick S, Gupta K, et al. Pleural multicystic mesothelial proliferation: a mimicker of benign peritoneal mesothelioma. Indian J Pathol Microbiol. 2013;56:476–7.

    Article  PubMed  Google Scholar 

  26. Alvarez-Fernandez E, Rabano A, Barros-Malvar JL, et al. Multicystic peritoneal mesothelioma: a case report. Histopathology. 1989;14:199–208.

    Article  CAS  PubMed  Google Scholar 

  27. Mennemeyer R, Smith M. Multicystic, peritoneal mesothelioma: a report with electron microscopy of a case mimicking intra-abdominal cystic hygroma (lymphangioma). Cancer. 1979;44:692–8.

    Article  CAS  PubMed  Google Scholar 

  28. Iversen OH, Hovig T, Brandtzaeg P. Peritoneal, benign, cystic mesothelioma with free-floating cysts, re-examined by new methods. Case Rep APMIS. 1988;96:123–7.

    CAS  Google Scholar 

  29. Shinozaki-Ushiku A, Ushiku T, Morita S, et al. Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma. Histopathology. 2017;70:722–33.

    Article  PubMed  Google Scholar 

  30. Daya D, McCaughey WT. Well-differentiated papillary mesothelioma of the peritoneum. A clinicopathologic study of 22 cases. Cancer. 1990;65:292–6.

    Article  CAS  PubMed  Google Scholar 

  31. Yesner R, Hurwitz A. Localized pleural mesothelioma of epithelial type. J Thorac Surg. 1953;26:325–9.

    Article  CAS  PubMed  Google Scholar 

  32. Butnor KJ, Sporn TA, Hammar SP, et al. Well-differentiated papillary mesothelioma. Am J Surg Pathol. 2001;25:1304–9.

    Article  CAS  PubMed  Google Scholar 

  33. Galateau-Sallé F, Vignaud JM, Burke L, Mesopath group, et al. Well-differentiated papillary mesothelioma of the pleura: a series of 24 cases. Am J Surg Pathol. 2004;28:534–40.

    Article  PubMed  Google Scholar 

  34. Sun M, Zhao L, Weng Lao I, et al. Well-differentiated papillary mesothelioma: a 17-year single institution experience with a series of 75 cases. Ann Diagn Pathol. 2019;38:43–50.

    Article  PubMed  Google Scholar 

  35. Chen X, Sheng W, Wang J. Well-differentiated papillary mesothelioma: a clinicopathological and immunohistochemical study of 18 cases with additional observation. Histopathology. 2013;62:805–13.

    Article  PubMed  Google Scholar 

  36. Barbera V, Rubino M. Papillary mesothelioma of the tunica vaginalis. Cancer. 1957;10:183–9.

    Article  CAS  PubMed  Google Scholar 

  37. Chetty R. Well differentiated (benign) papillary mesothelioma of the tunica vaginalis. J Clin Pathol. 1992;45:1029–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Brimo F, Illei PB, Epstein JI. Mesothelioma of the tunica vaginalis: a series of eight cases with uncertain malignant potential. Mod Pathol. 2010;23:1165–72.

    Article  PubMed  Google Scholar 

  39. Nemoto H, Tate G, Kishimoto K, et al. Heterozygous loss of NF2 is an early molecular alteration in well-differentiated papillary mesothelioma of the peritoneum. Cancer Genet. 2012;205:594–8.

    Article  CAS  PubMed  Google Scholar 

  40. Stevers M, Rabban JT, Garg K, et al. Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42. Mod Pathol. 2019;32:88–99.

    Article  CAS  PubMed  Google Scholar 

  41. Washimi K, Yokose T, Amitani Y, et al. Well-differentiated papillary mesothelioma, possibly giving rise to diffuse malignant mesothelioma: a case report. Pathol Int. 2013;63:220–5.

    Article  PubMed  Google Scholar 

  42. Costanzo L, Scarlata S, Perrone G, et al. Malignant transformation of well-differentiated papillary mesothelioma 13 years after the diagnosis: a case report. Clin Respir J. 2014;8:124–9.

    Article  PubMed  Google Scholar 

  43. Lee HE, Molina JR, Sukov WR, et al. BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma. Hum Pathol. 2018;79:168–76.

    Article  CAS  PubMed  Google Scholar 

  44. Churg A, Allen T, Borczuk AC, et al. Well-differentiated papillary mesothelioma with invasive foci. Am J Surg Pathol. 2014;38:990–8.

    Article  PubMed  Google Scholar 

  45. Lee YK, Jun HJ, Nahm JH, et al. Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum. Jpn J Clin Oncol. 2013;43:996–1003.

    Article  PubMed  Google Scholar 

  46. Churg A, Sheffield BS, Galateau-Salle F. New markers for separating benign from malignant mesothelial proliferations: are we there yet? Arch Pathol Lab Med. 2016;140:318–21.

    Article  CAS  PubMed  Google Scholar 

  47. Delgermaa V, Takahashi K, Park EK, et al. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89:716–24.

    Article  PubMed  PubMed Central  Google Scholar 

  48. English JC, Leslie KO. Pathology of the pleura. Clin Chest Med. 2006;27:157–80.

    Article  PubMed  Google Scholar 

  49. Cagle PT, Allen TC. Pathology of the pleura: what the pulmonologists need to know. Respirology. 2011;16:430–8.

    Article  PubMed  Google Scholar 

  50. Ai J, Stevenson JP. Current issues in malignant pleural mesothelioma evaluation and management. Oncologist. 2014;19:975–84.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Selikoff IJ, Churg J, Hammond EC. Relation between exposure to asbestos and mesothelioma. N Engl J Med. 1965;272:560–5.

    Article  CAS  PubMed  Google Scholar 

  52. Suster S, Moran C. Malignant mesothelioma: current status of histopathologic diagnosis and molecular profile. Expert Rev Mol Diagn. 2005;5:715–23.

    Article  CAS  PubMed  Google Scholar 

  53. Bernstein DM, Hoskins JA. The health effects of chrysotile: current perspective based upon recent data. Regul Toxicol Pharmacol. 2006;45:252–64.

    Article  CAS  PubMed  Google Scholar 

  54. Marchevsky AM, Wick MR. Current controversies regarding the role of asbestos exposure in the causation of malignant mesothelioma: the need for an evidence-based approach to develop medicolegal guidelines. Ann Diagn Pathol. 2003;7:321–32.

    Article  PubMed  Google Scholar 

  55. Ramazzini C. Asbestos is still with us: repeat call for a universal ban. Am J Ind Med. 2011;54:168–73.

    Article  CAS  PubMed  Google Scholar 

  56. Neumann V, Löseke S, Tannapfel A. Mesothelioma and analysis of tissue fiber content. Recent Results Cancer Res. 2011;189:79–95.

    Article  CAS  PubMed  Google Scholar 

  57. Leigh J, Davidson P, Hendrie L, et al. Malignant mesothelioma in Australia, 1945–2000. Am J Ind Med. 2002;41:188–201.

    Article  PubMed  Google Scholar 

  58. Tan C, Barrington S, Rankin S, et al. Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma. J Thorac Oncol. 2010;5:385–8.

    Article  PubMed  Google Scholar 

  59. Pesch B, Taeger D, Johnen G, et al. Cancer mortality in a surveillance cohort of German males formerly exposed to asbestos. Int J Hyg Environ Health. 2010;213:44–51.

    Article  PubMed  Google Scholar 

  60. Banaei A, Auvert B, Goldberg M, et al. Future trends in mortality of French men from mesothelioma. Occup Environ Med. 2000;57:488–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Larson T, Melnikova N, Davis SI, et al. Incidence and descriptive epidemiology of mesothelioma in the United States, 1999–2002. Int J Occup Environ Health. 2007;13:398–403.

    Article  PubMed  Google Scholar 

  62. Azuma K, Uchiyama I, Chiba Y, et al. Mesothelioma risk and environmental exposure to asbestos: past and future trends in Japan. Int J Occup Environ Health. 2009;15:166–72.

    Article  PubMed  Google Scholar 

  63. Pitarque S, Clèries R, Martínez JM, et al. Mesothelioma mortality in men: trends during 1977–2001 and projections for 2002–2016 in Spain. Occup Environ Med. 2008;65:279–82.

    Article  CAS  PubMed  Google Scholar 

  64. Segura O, Burdorf A, Looman C. Update of predictions of mortality from pleural mesothelioma in the Netherlands. Occup Environ Med. 2003;60:50–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer. 1980;46:2736–40.

    Article  CAS  PubMed  Google Scholar 

  66. Metintas S, Metintas M, Ucgun I, et al. Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area. Chest. 2002;122:2224–9.

    Article  PubMed  Google Scholar 

  67. Pan XL, Day HW, Wang W, et al. Residential proximity to naturally occurring asbestos and mesothelioma risk in California. Am J Respir Crit Care Med. 2005;172:1019–25.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Gulmez I, Kart L, Buyukoglan H, et al. Evaluation of malignant mesothelioma in central Anatolia: a study of 67 cases. Can Respir J. 2004;11:287–90.

    Article  PubMed  Google Scholar 

  69. Bourdès V, Boffetta P, Pisani P. Environmental exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis. Eur J Epidemiol. 2000;16:411–7.

    Article  PubMed  Google Scholar 

  70. Tward JD, Wendland MM, Shrieve DC, et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer. 2006;107:108–15.

    Article  PubMed  Google Scholar 

  71. Teta MJ, Lau E, Sceurman BK, et al. Therapeutic radiation for lymphoma: risk of malignant mesothelioma. Cancer. 2007;109:1432–8.

    Article  PubMed  Google Scholar 

  72. Gibb H, Fulcher K, Nagarajan S, et al. Analyses of radiation and mesothelioma in the US Transuranium and Uranium Registries. Am J Public Health. 2013;103:710–6.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Comar M, Zanotta N, Pesel G, et al. Asbestos and SV40 in malignant pleural mesothelioma from a hyperendemic area of north-eastern Italy. Tumori. 2012;98:210–4.

    Article  PubMed  Google Scholar 

  74. Cristaudo A, Foddis R, Vivaldi A, et al. SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. Cancer Res. 2005;65:3049–52.

    Article  CAS  PubMed  Google Scholar 

  75. Lundstig A, Dejmek A, Eklund C, et al. No detection of SV40 DNA in mesothelioma tissues from a high incidence area in Sweden. Anticancer Res. 2007;27:4159–61.

    CAS  PubMed  Google Scholar 

  76. Manfredi JJ, Dong J, Liu WJ, et al. Evidence against a role for SV40 in human mesothelioma. Cancer Res. 2005;65:2602–9.

    Article  CAS  PubMed  Google Scholar 

  77. Carbone M, Ferris LK, Baumann F, et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med. 2012;10:179.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43:1022–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43:668–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Desmeules P, Joubert P, Zhang L, et al. A subset of malignant mesotheliomas in young adults are associated with recurrent EWSR1/FUS-ATF1 fusions. Am J Surg Pathol. 2017;41:980–8.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Legha SS, Muggia FM. Pleural mesothelioma: clinical features and therapeutic implications. Ann Intern Med. 1977;87:613–21.

    Article  CAS  PubMed  Google Scholar 

  82. Grundy GW, Miller RW. Malignant mesothelioma in childhood. Report of 13 cases. Cancer. 1972;30:1216–8.

    Article  CAS  PubMed  Google Scholar 

  83. McDonald JC. Asbestos-related disease: an epidemiological review. IARC Sci Publ. 1980;2:587–601.

    Google Scholar 

  84. Borow M, Conston A, Livornese L, et al. Mesothelioma following exposure to asbestos: a review of 72 cases. Chest. 1973;64:641–6.

    Article  CAS  PubMed  Google Scholar 

  85. Brenner J, Sordillo PP, Magill GB, et al. Malignant mesothelioma of the pleura: review of 123 patients. Cancer. 1982;49:2431–5.

    Article  CAS  PubMed  Google Scholar 

  86. Adams VI, Unni KK, Muhm JR, et al. Diffuse malignant mesothelioma of pleura. Diagnosis and survival in 92 cases. Cancer. 1986;58:1540–51.

    Article  CAS  PubMed  Google Scholar 

  87. Elmes PC, Simpson JC. The clinical aspects of mesothelioma. Q J Med. 1976;45:427–49.

    CAS  PubMed  Google Scholar 

  88. Gill RR. Imaging of mesothelioma. Recent Results Cancer Res. 2011;189:27–43.

    Article  CAS  PubMed  Google Scholar 

  89. Dhalluin X, Scherpereel A. Chemotherapy and radiotherapy for mesothelioma. Recent Results Cancer Res. 2011;189:127–47.

    Article  CAS  PubMed  Google Scholar 

  90. Rice D. Surgical therapy of mesothelioma. Recent Results Cancer Res. 2011;189:97–125.

    Article  CAS  PubMed  Google Scholar 

  91. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113:723–31.

    Article  CAS  PubMed  Google Scholar 

  92. Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol. 1989;7:1157–68.

    Article  CAS  PubMed  Google Scholar 

  93. Cantin R, Al-Jabi M, McCaughey WT. Desmoplastic diffuse mesothelioma. Am J Surg Pathol. 1982;6:215–22.

    Article  CAS  PubMed  Google Scholar 

  94. Yates DH, Corrin B, Stidolph PN, et al. Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax. 1997;52:507–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Allen TC, Cagle PT, Churg AM, et al. Localized malignant mesothelioma. Am J Surg Pathol. 2005;29:866–73.

    Article  PubMed  Google Scholar 

  96. Guinee DG, Allen TC. Primary pleural neoplasia: entities other than diffuse malignant mesothelioma. Arch Pathol Lab Med. 2008;132:1149–70.

    Article  PubMed  Google Scholar 

  97. Gelvez-Zapata SM, Gaffney D, Scarci M, et al. What is the survival after surgery for localized malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg. 2013;16:533–7.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Amin MB, Edge S, Green F, et al., editors. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.

    Google Scholar 

  99. Rusch VW, Giroux D. Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database. Ann Cardiothorac Surg. 2012;1:438–48.

    PubMed  PubMed Central  Google Scholar 

  100. Hourihane DO. A biopsy series of mesotheliomata, and attempts to identify asbestos within some of the tumors. Ann N Y Acad Sci. 1965;132:647–73.

    Article  CAS  PubMed  Google Scholar 

  101. van Ruth S, Baas P, Zoetmulder FA. Surgical treatment of malignant pleural mesothelioma: a review. Chest. 2003;123:551–61.

    Article  PubMed  Google Scholar 

  102. Crotty TB, Myers JL, Katzenstein AL, et al. Localized malignant mesothelioma. A clinicopathologic and flow cytometric study. Am J Surg Pathol. 1994;18:357–63.

    Article  CAS  PubMed  Google Scholar 

  103. Enzinger FM, Weiss SW. Soft tissue tumours. 3rd ed. St Louis: Mosby; 1995. p. 787–819.

    Google Scholar 

  104. Battifora H, McCaughey WTE. Tumours and pseudotumours of the serosal membranes. In: Atlas of tumour pathology, 3rd series, fascicle 15. Washington, DC: Armed Forces Institute of Pathology; 1995. p. 15–88.

    Google Scholar 

  105. Gibbs AR, Whimster WF. Tumours of the lung and pleura. In: Fletcher CDM, editor. Diagnostic histopathology of tumors, vol. 1. Edinburgh: Churchill Livingstone; 1995. p. 127–50.

    Google Scholar 

  106. Attanoos RL, Gibbs AR. Pathology of malignant mesothelioma. Histopathology. 1997;30:403–18.

    Article  CAS  PubMed  Google Scholar 

  107. McCaughey WT. Asbestos and neoplasia: diffuse mesothelial tumors. Criteria for diagnosis of diffuse mesothelial tumors. Ann N Y Acad Sci. 1965;132:603–13.

    Article  CAS  PubMed  Google Scholar 

  108. Kannerstein M, McCaughey WT, Churg J, et al. A critique of the criteria for the diagnosis of diffuse malignant mesothelioma. Mt Sinai J Med. 1977;44:485–94.

    CAS  PubMed  Google Scholar 

  109. Shanks JH, Harris M, Banerjee SS, et al. Mesotheliomas with deciduoid morphology: a morphologic spectrum and a variant not confined to young females. Am J Surg Pathol. 2000;24:285–94.

    Article  CAS  PubMed  Google Scholar 

  110. Ordóñez NG. Epithelial mesothelioma with deciduoid features: report of four cases. Am J Surg Pathol. 2000;24:816–23.

    Article  PubMed  Google Scholar 

  111. Ordóñez NG. Mesothelioma with signet-ring cell features: report of 23 cases. Mod Pathol. 2013;26:370–84.

    Article  PubMed  CAS  Google Scholar 

  112. Ordóñez NG, Myhre M, Mackay B. Clear cell mesothelioma. Ultrastruct Pathol. 1996;20:331–6.

    Article  PubMed  Google Scholar 

  113. Ordóñez NG. Mesothelioma with rhabdoid features: an ultrastructural and immunohistochemical study of 10 cases. Mod Pathol. 2006;19:373–83.

    Article  PubMed  Google Scholar 

  114. Mayall FG, Gibbs AR. The histology and immunohistochemistry of small cell mesothelioma. Histopathology. 1992;20:47–51.

    Article  CAS  PubMed  Google Scholar 

  115. Ordóñez NG. Pleomorphic mesothelioma: report of 10 cases. Mod Pathol. 2012;25:1011–22.

    Article  PubMed  Google Scholar 

  116. Henderson DW, Attwood HD, Constance TJ, et al. Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma. Ultrastruct Pathol. 1988;12:367–84.

    Article  CAS  PubMed  Google Scholar 

  117. Wilson GE, Hasleton PS, Chatterjee AK. Desmoplastic malignant mesothelioma: a review of 17 cases. J Clin Pathol. 1992;45:295–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Klebe S, Mahar A, Henderson DW, et al. Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review. Mod Pathol. 2008;21:1084–94.

    Article  PubMed  Google Scholar 

  119. Kannerstein M, Churg J, Magner D. Histochemistry in the diagnosis of malignant mesothelioma. Ann Clin Lab Sci. 1973;3:207–11.

    CAS  PubMed  Google Scholar 

  120. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 2003;27:1031–51.

    Article  PubMed  Google Scholar 

  121. Klebe S, Brownlee NA, Mahar A, et al. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. Mod Pathol. 2010;23:470–9.

    Article  PubMed  Google Scholar 

  122. Ordóñez NG. Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update. Hum Pathol. 2013;44:1–19.

    Article  PubMed  CAS  Google Scholar 

  123. Walts AE, Said JW, Shintaku IP. Epithelial membrane antigen in the cytodiagnosis of effusions and aspirates: immunocytochemical and ultrastructural localization in benign and malignant cells. Diagn Cytopathol. 1987;3:41–9.

    Article  CAS  PubMed  Google Scholar 

  124. Kafiri G, Thomas DM, Shepherd NA, et al. p53 expression is common in malignant mesothelioma. Histopathology. 1992;21:331–4.

    Article  CAS  PubMed  Google Scholar 

  125. Mayall FG, Goddard H, Gibbs AR. The frequency of p53 immunostaining in asbestos-associated mesotheliomas and non-asbestos-associated mesotheliomas. Histopathology. 1993;22:383.

    Article  CAS  PubMed  Google Scholar 

  126. Sheffield BS, Hwang HC, Lee AF, et al. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol. 2015;39(7):977–82.

    Article  PubMed  Google Scholar 

  127. Yoshikawa Y, Sato A, Tsujimura T, et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci. 2012;103:868–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Nasu M, Emi M, Pastorino S, et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol. 2015;10:565–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. McGregor SM, Dunning R, Hyjek E, et al. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma. Hum Pathol. 2015;46:1670–8.

    Article  CAS  PubMed  Google Scholar 

  130. Farzin M, Toon CW, Clarkson A, et al. Loss of expression of BAP1 predicts longer survival in mesothelioma. Pathology. 2015;47:302–7.

    Article  CAS  PubMed  Google Scholar 

  131. Cigognetti M, Lonardi S, Fisogni S, et al. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol. 2015;28:1043–57.

    Article  CAS  PubMed  Google Scholar 

  132. Hwang HC, Sheffield BS, Rodriguez S, et al. Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens. Am J Surg Pathol. 2016;40:120–6.

    Article  PubMed  Google Scholar 

  133. Joseph NM, Chen YY, Nasr A, et al. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. Mod Pathol. 2017;30:246–54.

    Article  CAS  PubMed  Google Scholar 

  134. Guo G, Chmielecki J, Goparaju C, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015;75:264–9.

    Article  CAS  PubMed  Google Scholar 

  135. Ladanyi M, Zauderer MG, Krug LM, et al. New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. Clin Cancer Res. 2012;18:4485–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Ladanyi M. Implications of P16/CDKN2A deletion in pleural mesotheliomas. Lung Cancer. 2005;49:S95–8.

    Article  PubMed  Google Scholar 

  137. Wu D, Hiroshima K, Matsumoto S, et al. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis. Am J Clin Pathol. 2013;139:39–46.

    Article  CAS  PubMed  Google Scholar 

  138. Tochigi N, Attanoos R, Chirieac LR, et al. p16 Deletion in sarcomatoid tumors of the lung and pleura. Arch Pathol Lab Med. 2013;137:632–6.

    Article  PubMed  Google Scholar 

  139. Panani AD, Maliaga K, Babanaraki A, et al. Numerical abnormalities of chromosome 9 and p16CDKN2A gene deletion detected by FISH in non-small cell lung cancer. Anticancer Res. 2009;29:4483–7.

    PubMed  Google Scholar 

  140. Conway C, Beswick S, Elliott F, et al. Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma. Genes Chromosomes Cancer. 2010;49:425–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. Mohseny AB, Tieken C, van der Velden PA, et al. Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma. Genes Chromosomes Cancer. 2010;49:1095–103.

    Article  CAS  PubMed  Google Scholar 

  142. Murali R, Wiesner T, Scolyer RA. Tumours associated with BAP1 mutations. Pathology. 2013;45:116–26.

    Article  CAS  PubMed  Google Scholar 

  143. Njauw CN, Kim I, Piris A, et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One. 2012;7:e35295.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. Panagopoulos I, Thorsen J, Gorunova L, et al. RNA sequencing identifies fusion of the EWSR1 and YY1 genes in mesothelioma with t(14;22)(q32;q12). Genes Chromosomes Cancer. 2013;52:733–40.

    Article  CAS  PubMed  Google Scholar 

  145. Sahn SA. State of the art. The pleura. Am Rev Respir Dis. 1988;138:184–234.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Associate Professor, Department of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Annikka Weissferdt

Authors
  1. Annikka Weissferdt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Annikka Weissferdt .

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Weissferdt, A. (2020). Mesothelial Tumors of the Pleura. In: Diagnostic Thoracic Pathology. Springer, Cham. https://doi.org/10.1007/978-3-030-36438-0_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-36438-0_22

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-36437-3

  • Online ISBN: 978-3-030-36438-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation